[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fwLyj0TUMe-8Z2Tf9xPo8HvSeap6f44jPqpyeSJz_dSQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":75,"rows":82},"Institute of Tropical Medicine, Belgium",[4],99,false,19,21,413401,15,68,[14,17,20,22,25,27,30,32],{"name":15,"count":16},"Malaria",6,{"name":18,"count":19},"Malaria in Pregnancy",5,{"name":21,"count":19},"Cutaneous Leishmaniases",{"name":23,"count":24},"Leprosy",4,{"name":26,"count":24},"Fever",{"name":28,"count":29},"Visceral Leishmaniasis",3,{"name":31,"count":29},"Mpox (Monkeypox)",{"name":33,"count":29},"HIV Infections",[35,40,45,50,55,60,65,70],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04260477","Novel Triple-dose Tuberculosis Retreatment Regimen","2025-06","6EH³R³Z",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06514560","OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients","2025-12-30","Miltefosine",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06839989","An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC","2026-05-20","Mpox vaccination with MVA-BN",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06126822","Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno\u002FMvabea® or Ervebo® Vaccine Schedules in DRC","2026-10","Zabdeno® booster",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06695143","Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia","2027-03","Fusidic Acid",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05597280","Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy","2027-03-15","BE-PEP Bedaquiline",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT07455318","Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.","2027-06","Booster vaccination",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT07463040","Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)","2029-03-01","Sodium Stibogluconate",[76,77,78,79,80,81],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[83,130,152,170,188,206,224,242,260,282,300,321,347,365,387,409,459,487,513,531,549,590,612,636,654,672,697,715,740,767,785,810,828,846,864,882,908,933,960,978,996,1021,1039,1063,1089,1115,1140,1165,1191],{"intervention":44,"totalTrials":29,"cells":84},{"EARLY_PHASE1":85,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":107,"NA":109},{"trials":86,"activeCount":87},[],0,{"trials":89,"activeCount":87},[],{"trials":91,"activeCount":87},[],{"trials":93,"activeCount":106,"soonestReadout":73},[94],{"nctId":71,"briefTitle":72,"status":95,"phases":96,"primaryCompletion":73,"completion":97,"start":98,"enrollment":99,"conditions":100,"interventions":102},"NOT_YET_RECRUITING",[79],"2029-08-31","2027-01-01",900,[101],"Cutaneous Leihmaniasis",[74,44,103,104,105],"Miltefosine + Paromomycin","Liposomal Amphotericin B","Pentamidine isethionate",1,{"trials":108,"activeCount":87},[],{"trials":110,"activeCount":106,"soonestReadout":43},[111,122],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":121},"NCT04004754","Outcomes of Complicated CL in Ethiopia Treated With Miltefosine","COMPLETED",[],"2020-04-01","2020-06-11","2019-05-07",94,[21],[44],{"nctId":41,"briefTitle":42,"status":123,"phases":124,"primaryCompletion":43,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":129},"RECRUITING",[],"2026-12-30","2024-06-18",80,[21],[44],{"intervention":64,"totalTrials":106,"cells":131},{"EARLY_PHASE1":132,"PHASE1":134,"PHASE2":136,"PHASE3":138,"PHASE4":148,"NA":150},{"trials":133,"activeCount":87},[],{"trials":135,"activeCount":87},[],{"trials":137,"activeCount":87},[],{"trials":139,"activeCount":106,"soonestReadout":63},[140],{"nctId":61,"briefTitle":62,"status":123,"phases":141,"primaryCompletion":63,"completion":63,"start":142,"enrollment":143,"conditions":144,"interventions":145},[79],"2023-03-22",124000,[23],[64,146,147],"SDR-PEP Rifampicin","BE-PEP Rifampicin",{"trials":149,"activeCount":87},[],{"trials":151,"activeCount":87},[],{"intervention":146,"totalTrials":106,"cells":153},{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":166,"NA":168},{"trials":155,"activeCount":87},[],{"trials":157,"activeCount":87},[],{"trials":159,"activeCount":87},[],{"trials":161,"activeCount":106,"soonestReadout":63},[162],{"nctId":61,"briefTitle":62,"status":123,"phases":163,"primaryCompletion":63,"completion":63,"start":142,"enrollment":143,"conditions":164,"interventions":165},[79],[23],[64,146,147],{"trials":167,"activeCount":87},[],{"trials":169,"activeCount":87},[],{"intervention":147,"totalTrials":106,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":184,"NA":186},{"trials":173,"activeCount":87},[],{"trials":175,"activeCount":87},[],{"trials":177,"activeCount":87},[],{"trials":179,"activeCount":106,"soonestReadout":63},[180],{"nctId":61,"briefTitle":62,"status":123,"phases":181,"primaryCompletion":63,"completion":63,"start":142,"enrollment":143,"conditions":182,"interventions":183},[79],[23],[64,146,147],{"trials":185,"activeCount":87},[],{"trials":187,"activeCount":87},[],{"intervention":74,"totalTrials":106,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":202,"NA":204},{"trials":191,"activeCount":87},[],{"trials":193,"activeCount":87},[],{"trials":195,"activeCount":87},[],{"trials":197,"activeCount":106,"soonestReadout":73},[198],{"nctId":71,"briefTitle":72,"status":95,"phases":199,"primaryCompletion":73,"completion":97,"start":98,"enrollment":99,"conditions":200,"interventions":201},[79],[101],[74,44,103,104,105],{"trials":203,"activeCount":87},[],{"trials":205,"activeCount":87},[],{"intervention":103,"totalTrials":106,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":220,"NA":222},{"trials":209,"activeCount":87},[],{"trials":211,"activeCount":87},[],{"trials":213,"activeCount":87},[],{"trials":215,"activeCount":106,"soonestReadout":73},[216],{"nctId":71,"briefTitle":72,"status":95,"phases":217,"primaryCompletion":73,"completion":97,"start":98,"enrollment":99,"conditions":218,"interventions":219},[79],[101],[74,44,103,104,105],{"trials":221,"activeCount":87},[],{"trials":223,"activeCount":87},[],{"intervention":104,"totalTrials":106,"cells":225},{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":232,"PHASE4":238,"NA":240},{"trials":227,"activeCount":87},[],{"trials":229,"activeCount":87},[],{"trials":231,"activeCount":87},[],{"trials":233,"activeCount":106,"soonestReadout":73},[234],{"nctId":71,"briefTitle":72,"status":95,"phases":235,"primaryCompletion":73,"completion":97,"start":98,"enrollment":99,"conditions":236,"interventions":237},[79],[101],[74,44,103,104,105],{"trials":239,"activeCount":87},[],{"trials":241,"activeCount":87},[],{"intervention":105,"totalTrials":106,"cells":243},{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":250,"PHASE4":256,"NA":258},{"trials":245,"activeCount":87},[],{"trials":247,"activeCount":87},[],{"trials":249,"activeCount":87},[],{"trials":251,"activeCount":106,"soonestReadout":73},[252],{"nctId":71,"briefTitle":72,"status":95,"phases":253,"primaryCompletion":73,"completion":97,"start":98,"enrollment":99,"conditions":254,"interventions":255},[79],[101],[74,44,103,104,105],{"trials":257,"activeCount":87},[],{"trials":259,"activeCount":87},[],{"intervention":54,"totalTrials":106,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":278,"NA":280},{"trials":263,"activeCount":87},[],{"trials":265,"activeCount":87},[],{"trials":267,"activeCount":87},[],{"trials":269,"activeCount":106,"soonestReadout":53},[270],{"nctId":51,"briefTitle":52,"status":123,"phases":271,"primaryCompletion":53,"completion":53,"start":272,"enrollment":273,"conditions":274,"interventions":276},[79],"2025-02-25",624,[275],"Ebola Virus Disease",[54,277],"Ervebo® booster",{"trials":279,"activeCount":87},[],{"trials":281,"activeCount":87},[],{"intervention":277,"totalTrials":106,"cells":283},{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":296,"NA":298},{"trials":285,"activeCount":87},[],{"trials":287,"activeCount":87},[],{"trials":289,"activeCount":87},[],{"trials":291,"activeCount":106,"soonestReadout":53},[292],{"nctId":51,"briefTitle":52,"status":123,"phases":293,"primaryCompletion":53,"completion":53,"start":272,"enrollment":273,"conditions":294,"interventions":295},[79],[275],[54,277],{"trials":297,"activeCount":87},[],{"trials":299,"activeCount":87},[],{"intervention":69,"totalTrials":106,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":317,"NA":319},{"trials":303,"activeCount":87},[],{"trials":305,"activeCount":87},[],{"trials":307,"activeCount":87},[],{"trials":309,"activeCount":106,"soonestReadout":68},[310],{"nctId":66,"briefTitle":67,"status":95,"phases":311,"primaryCompletion":68,"completion":68,"start":312,"enrollment":313,"conditions":314,"interventions":316},[79],"2026-05-15",561,[315],"Rabies (Healthy Volunteers)",[69],{"trials":318,"activeCount":87},[],{"trials":320,"activeCount":87},[],{"intervention":39,"totalTrials":106,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":343,"NA":345},{"trials":324,"activeCount":87},[],{"trials":326,"activeCount":87},[],{"trials":328,"activeCount":87},[],{"trials":330,"activeCount":106,"soonestReadout":38},[331],{"nctId":36,"briefTitle":37,"status":123,"phases":332,"primaryCompletion":38,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":341},[79],"2025-09","2021-03-01",370,[337,338,339,340],"Multidrug-resistant Tuberculosis","Pulmonary Tuberculosis","Tuberculosis","Resistance to Tuberculostatic Drugs",[39,342],"6EHRZ",{"trials":344,"activeCount":87},[],{"trials":346,"activeCount":87},[],{"intervention":342,"totalTrials":106,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":361,"NA":363},{"trials":350,"activeCount":87},[],{"trials":352,"activeCount":87},[],{"trials":354,"activeCount":87},[],{"trials":356,"activeCount":106,"soonestReadout":38},[357],{"nctId":36,"briefTitle":37,"status":123,"phases":358,"primaryCompletion":38,"completion":333,"start":334,"enrollment":335,"conditions":359,"interventions":360},[79],[337,338,339,340],[39,342],{"trials":362,"activeCount":87},[],{"trials":364,"activeCount":87},[],{"intervention":59,"totalTrials":106,"cells":366},{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":383,"NA":385},{"trials":368,"activeCount":87},[],{"trials":370,"activeCount":87},[],{"trials":372,"activeCount":87},[],{"trials":374,"activeCount":106,"soonestReadout":58},[375],{"nctId":56,"briefTitle":57,"status":95,"phases":376,"primaryCompletion":58,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":382},[79],"2027-04","2025-04",180,[381],"Leishmaniasis, Cutaneous",[59],{"trials":384,"activeCount":87},[],{"trials":386,"activeCount":87},[],{"intervention":49,"totalTrials":106,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":403,"PHASE4":405,"NA":407},{"trials":390,"activeCount":87},[],{"trials":392,"activeCount":87},[],{"trials":394,"activeCount":106,"soonestReadout":48},[395],{"nctId":46,"briefTitle":47,"status":396,"phases":397,"primaryCompletion":48,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":402},"ACTIVE_NOT_RECRUITING",[78],"2026-11-30","2025-08-04",600,[31],[49],{"trials":404,"activeCount":87},[],{"trials":406,"activeCount":87},[],{"trials":408,"activeCount":87},[],{"intervention":410,"totalTrials":29,"cells":411},"Sulfadoxine-Pyrimethamine",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":445,"NA":457},{"trials":413,"activeCount":87},[],{"trials":415,"activeCount":87},[],{"trials":417,"activeCount":87},[],{"trials":419,"activeCount":87},[420,433],{"nctId":421,"briefTitle":422,"status":423,"phases":424,"primaryCompletion":425,"completion":426,"start":427,"enrollment":428,"conditions":429,"interventions":430},"NCT00711906","Daily Co-trimoxazole Prophylaxis to Prevent Malaria in Pregnancy","TERMINATED",[79],"2010-02","2010-09","2009-02",352,[18],[431,432],"Cotrimoxazole","Sulfadoxine-pyrimethamine",{"nctId":434,"briefTitle":435,"status":114,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":442},"NCT00730366","New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa",[79],"2006-10","2006-12","2004-03",2766,[18],[443,444],"sulfadoxine-pyrimethamine","Chloroquine",{"trials":446,"activeCount":87},[447],{"nctId":448,"briefTitle":449,"status":114,"phases":450,"primaryCompletion":451,"completion":451,"start":452,"enrollment":453,"conditions":454,"interventions":456},"NCT00372632","IPT of Malaria With SP in Different Zones of Drug Resistance in Rwanda",[80],"2008-04","2005-12",1717,[455],"Non HIV Infected Pregnant Women",[410],{"trials":458,"activeCount":87},[],{"intervention":444,"totalTrials":460,"cells":461},2,{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":474,"NA":485},{"trials":463,"activeCount":87},[],{"trials":465,"activeCount":87},[],{"trials":467,"activeCount":87},[],{"trials":469,"activeCount":87},[470],{"nctId":434,"briefTitle":435,"status":114,"phases":471,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":472,"interventions":473},[79],[18],[443,444],{"trials":475,"activeCount":87},[476],{"nctId":477,"briefTitle":478,"status":114,"phases":479,"primaryCompletion":437,"completion":437,"start":480,"enrollment":481,"conditions":482,"interventions":483},"NCT00680732","Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component",[80],"2003-06",1370,[15,18],[444,484],"Sulphadoxyne-pyrimethamine",{"trials":486,"activeCount":87},[],{"intervention":488,"totalTrials":106,"cells":489},"Rocephin",{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":498,"NA":511},{"trials":491,"activeCount":87},[],{"trials":493,"activeCount":87},[],{"trials":495,"activeCount":87},[],{"trials":497,"activeCount":87},[],{"trials":499,"activeCount":87},[500],{"nctId":501,"briefTitle":502,"status":114,"phases":503,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":509},"NCT05027516","Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea",[80],"2022-05-09","2022-01-17",42,[508],"Neisseria Gonorrhoeae",[488,510],"Azithromycin",{"trials":512,"activeCount":87},[],{"intervention":510,"totalTrials":106,"cells":514},{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":523,"NA":529},{"trials":516,"activeCount":87},[],{"trials":518,"activeCount":87},[],{"trials":520,"activeCount":87},[],{"trials":522,"activeCount":87},[],{"trials":524,"activeCount":87},[525],{"nctId":501,"briefTitle":502,"status":114,"phases":526,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":527,"interventions":528},[80],[508],[488,510],{"trials":530,"activeCount":87},[],{"intervention":484,"totalTrials":106,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":539,"PHASE4":541,"NA":547},{"trials":534,"activeCount":87},[],{"trials":536,"activeCount":87},[],{"trials":538,"activeCount":87},[],{"trials":540,"activeCount":87},[],{"trials":542,"activeCount":87},[543],{"nctId":477,"briefTitle":478,"status":114,"phases":544,"primaryCompletion":437,"completion":437,"start":480,"enrollment":481,"conditions":545,"interventions":546},[80],[15,18],[444,484],{"trials":548,"activeCount":87},[],{"intervention":550,"totalTrials":460,"cells":551},"Dihydroartemisinin-piperaquine",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":586,"NA":588},{"trials":553,"activeCount":87},[],{"trials":555,"activeCount":87},[],{"trials":557,"activeCount":87},[],{"trials":559,"activeCount":87},[560,573],{"nctId":561,"briefTitle":562,"status":114,"phases":563,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":569},"NCT00852423","Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria",[79],"2013-10","2015-04","2010-06",3428,[18],[550,570,571,572],"Artesunate-mefloquine","Artesunate-amodiaquine","Artemether-lumefantrine",{"nctId":574,"briefTitle":575,"status":114,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT00393679","Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children",[79],"2009-12","2007-07",4112,[26,15],[582,583,584,585],"amodiaquine-artesunate","dihydroartemisinin-piperaquine","artemether-lumefantrine","Lapdap",{"trials":587,"activeCount":87},[],{"trials":589,"activeCount":87},[],{"intervention":572,"totalTrials":460,"cells":591},{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":608,"NA":610},{"trials":593,"activeCount":87},[],{"trials":595,"activeCount":87},[],{"trials":597,"activeCount":87},[],{"trials":599,"activeCount":87},[600,604],{"nctId":561,"briefTitle":562,"status":114,"phases":601,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":602,"interventions":603},[79],[18],[550,570,571,572],{"nctId":574,"briefTitle":575,"status":114,"phases":605,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":606,"interventions":607},[79],[26,15],[582,583,584,585],{"trials":609,"activeCount":87},[],{"trials":611,"activeCount":87},[],{"intervention":613,"totalTrials":106,"cells":614},"Rifampicin",{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":621,"PHASE4":632,"NA":634},{"trials":616,"activeCount":87},[],{"trials":618,"activeCount":87},[],{"trials":620,"activeCount":87},[],{"trials":622,"activeCount":87},[623],{"nctId":624,"briefTitle":625,"status":114,"phases":626,"primaryCompletion":627,"completion":627,"start":628,"enrollment":629,"conditions":630,"interventions":631},"NCT03662022","Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar",[79],"2023-01-17","2019-01-02",144000,[23],[613],{"trials":633,"activeCount":87},[],{"trials":635,"activeCount":87},[],{"intervention":570,"totalTrials":106,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":650,"NA":652},{"trials":639,"activeCount":87},[],{"trials":641,"activeCount":87},[],{"trials":643,"activeCount":87},[],{"trials":645,"activeCount":87},[646],{"nctId":561,"briefTitle":562,"status":114,"phases":647,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":648,"interventions":649},[79],[18],[550,570,571,572],{"trials":651,"activeCount":87},[],{"trials":653,"activeCount":87},[],{"intervention":571,"totalTrials":106,"cells":655},{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":668,"NA":670},{"trials":657,"activeCount":87},[],{"trials":659,"activeCount":87},[],{"trials":661,"activeCount":87},[],{"trials":663,"activeCount":87},[664],{"nctId":561,"briefTitle":562,"status":114,"phases":665,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":666,"interventions":667},[79],[18],[550,570,571,572],{"trials":669,"activeCount":87},[],{"trials":671,"activeCount":87},[],{"intervention":673,"totalTrials":106,"cells":674},"Cotrimoxazole prophylaxis",{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":693,"NA":695},{"trials":676,"activeCount":87},[],{"trials":678,"activeCount":87},[],{"trials":680,"activeCount":87},[],{"trials":682,"activeCount":87},[683],{"nctId":684,"briefTitle":685,"status":114,"phases":686,"primaryCompletion":687,"completion":688,"start":426,"enrollment":689,"conditions":690,"interventions":691},"NCT01053325","Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy",[79],"2012-12","2013-02",848,[18,33],[673,692],"SP IPT",{"trials":694,"activeCount":87},[],{"trials":696,"activeCount":87},[],{"intervention":692,"totalTrials":106,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":711,"NA":713},{"trials":700,"activeCount":87},[],{"trials":702,"activeCount":87},[],{"trials":704,"activeCount":87},[],{"trials":706,"activeCount":87},[707],{"nctId":684,"briefTitle":685,"status":114,"phases":708,"primaryCompletion":687,"completion":688,"start":426,"enrollment":689,"conditions":709,"interventions":710},[79],[18,33],[673,692],{"trials":712,"activeCount":87},[],{"trials":714,"activeCount":87},[],{"intervention":716,"totalTrials":106,"cells":717},"Mefloquine-artesunate",{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":724,"PHASE4":736,"NA":738},{"trials":719,"activeCount":87},[],{"trials":721,"activeCount":87},[],{"trials":723,"activeCount":87},[],{"trials":725,"activeCount":87},[726],{"nctId":727,"briefTitle":728,"status":114,"phases":729,"primaryCompletion":730,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":735},"NCT00701961","Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy",[78,79],"2009-07","2008-10",48,[734],"Plasmodium Falciparum Malaria",[716],{"trials":737,"activeCount":87},[],{"trials":739,"activeCount":87},[],{"intervention":741,"totalTrials":106,"cells":742},"Praziquantel",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":763,"NA":765},{"trials":744,"activeCount":87},[],{"trials":746,"activeCount":87},[],{"trials":748,"activeCount":87},[],{"trials":750,"activeCount":87},[751],{"nctId":752,"briefTitle":753,"status":114,"phases":754,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":758,"interventions":761},"NCT03893097","Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children",[79],"2021-03-04","2019-10-14",726,[759,760],"Schistosoma Haematobium","Schistosoma Mansoni",[741,762],"Artesunate + Mefloquine",{"trials":764,"activeCount":87},[],{"trials":766,"activeCount":87},[],{"intervention":762,"totalTrials":106,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":781,"NA":783},{"trials":770,"activeCount":87},[],{"trials":772,"activeCount":87},[],{"trials":774,"activeCount":87},[],{"trials":776,"activeCount":87},[777],{"nctId":752,"briefTitle":753,"status":114,"phases":778,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":779,"interventions":780},[79],[759,760],[741,762],{"trials":782,"activeCount":87},[],{"trials":784,"activeCount":87},[],{"intervention":786,"totalTrials":106,"cells":787},"Dihydroartemisin-piperaquine",{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":806,"NA":808},{"trials":789,"activeCount":87},[],{"trials":791,"activeCount":87},[],{"trials":793,"activeCount":87},[],{"trials":795,"activeCount":87},[796],{"nctId":797,"briefTitle":798,"status":114,"phases":799,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":803,"interventions":804},"NCT00373607","Efficacy and Safety of Dihydroartemisinin\u002FPiperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru",[79],"2005-07","2003-07",522,[15],[786,805],"Mefloquine + Artesunate",{"trials":807,"activeCount":87},[],{"trials":809,"activeCount":87},[],{"intervention":805,"totalTrials":106,"cells":811},{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":818,"PHASE4":824,"NA":826},{"trials":813,"activeCount":87},[],{"trials":815,"activeCount":87},[],{"trials":817,"activeCount":87},[],{"trials":819,"activeCount":87},[820],{"nctId":797,"briefTitle":798,"status":114,"phases":821,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":822,"interventions":823},[79],[15],[786,805],{"trials":825,"activeCount":87},[],{"trials":827,"activeCount":87},[],{"intervention":582,"totalTrials":106,"cells":829},{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":842,"NA":844},{"trials":831,"activeCount":87},[],{"trials":833,"activeCount":87},[],{"trials":835,"activeCount":87},[],{"trials":837,"activeCount":87},[838],{"nctId":574,"briefTitle":575,"status":114,"phases":839,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":840,"interventions":841},[79],[26,15],[582,583,584,585],{"trials":843,"activeCount":87},[],{"trials":845,"activeCount":87},[],{"intervention":585,"totalTrials":106,"cells":847},{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":860,"NA":862},{"trials":849,"activeCount":87},[],{"trials":851,"activeCount":87},[],{"trials":853,"activeCount":87},[],{"trials":855,"activeCount":87},[856],{"nctId":574,"briefTitle":575,"status":114,"phases":857,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":858,"interventions":859},[79],[26,15],[582,583,584,585],{"trials":861,"activeCount":87},[],{"trials":863,"activeCount":87},[],{"intervention":431,"totalTrials":106,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":872,"PHASE4":878,"NA":880},{"trials":867,"activeCount":87},[],{"trials":869,"activeCount":87},[],{"trials":871,"activeCount":87},[],{"trials":873,"activeCount":87},[874],{"nctId":421,"briefTitle":422,"status":423,"phases":875,"primaryCompletion":425,"completion":426,"start":427,"enrollment":428,"conditions":876,"interventions":877},[79],[18],[431,432],{"trials":879,"activeCount":87},[],{"trials":881,"activeCount":87},[],{"intervention":883,"totalTrials":106,"cells":884},"Pentamidine",{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":891,"PHASE4":904,"NA":906},{"trials":886,"activeCount":87},[],{"trials":888,"activeCount":87},[],{"trials":890,"activeCount":87},[],{"trials":892,"activeCount":87},[893],{"nctId":894,"briefTitle":895,"status":114,"phases":896,"primaryCompletion":897,"completion":897,"start":898,"enrollment":899,"conditions":900,"interventions":903},"NCT01360762","Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study",[79],"2015-11","2011-11",74,[901,902],"Visceral Leishmaniosis","HIV-infection\u002FAids",[883],{"trials":905,"activeCount":87},[],{"trials":907,"activeCount":87},[],{"intervention":909,"totalTrials":106,"cells":910},"Human Diploid Cell Vaccine (HDCV) rabies vaccine",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":929,"NA":931},{"trials":912,"activeCount":87},[],{"trials":914,"activeCount":87},[],{"trials":916,"activeCount":87},[],{"trials":918,"activeCount":87},[919],{"nctId":920,"briefTitle":921,"status":114,"phases":922,"primaryCompletion":923,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":928},"NCT01388985","Simplifying the Rabies Pre-exposure Vaccination",[79],"2016-01","2011-10",500,[927],"Rabies",[909],{"trials":930,"activeCount":87},[],{"trials":932,"activeCount":87},[],{"intervention":934,"totalTrials":106,"cells":935},"6EH³RZ",{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":942,"PHASE4":956,"NA":958},{"trials":937,"activeCount":87},[],{"trials":939,"activeCount":87},[],{"trials":941,"activeCount":87},[],{"trials":943,"activeCount":87},[944],{"nctId":945,"briefTitle":946,"status":947,"phases":948,"primaryCompletion":949,"completion":949,"start":950,"enrollment":87,"conditions":951,"interventions":953},"NCT03862248","Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More","WITHDRAWN",[79],"2022-10-01","2019-09-30",[952],"Tuberculosis, Pulmonary",[934,954,955],"6EHR³Z","6EHRZLfx",{"trials":957,"activeCount":87},[],{"trials":959,"activeCount":87},[],{"intervention":954,"totalTrials":106,"cells":961},{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":966,"PHASE3":968,"PHASE4":974,"NA":976},{"trials":963,"activeCount":87},[],{"trials":965,"activeCount":87},[],{"trials":967,"activeCount":87},[],{"trials":969,"activeCount":87},[970],{"nctId":945,"briefTitle":946,"status":947,"phases":971,"primaryCompletion":949,"completion":949,"start":950,"enrollment":87,"conditions":972,"interventions":973},[79],[952],[934,954,955],{"trials":975,"activeCount":87},[],{"trials":977,"activeCount":87},[],{"intervention":955,"totalTrials":106,"cells":979},{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":992,"NA":994},{"trials":981,"activeCount":87},[],{"trials":983,"activeCount":87},[],{"trials":985,"activeCount":87},[],{"trials":987,"activeCount":87},[988],{"nctId":945,"briefTitle":946,"status":947,"phases":989,"primaryCompletion":949,"completion":949,"start":950,"enrollment":87,"conditions":990,"interventions":991},[79],[952],[934,954,955],{"trials":993,"activeCount":87},[],{"trials":995,"activeCount":87},[],{"intervention":997,"totalTrials":106,"cells":998},"BE-PEP",{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":1000,"activeCount":87},[],{"trials":1002,"activeCount":87},[],{"trials":1004,"activeCount":87},[1005],{"nctId":1006,"briefTitle":1007,"status":114,"phases":1008,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1013},"NCT05406479","Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)",[78],"2023-01-26","2022-07-14",313,[23],[997,1014,997],"SDR-PEP",{"trials":1016,"activeCount":87},[],{"trials":1018,"activeCount":87},[],{"trials":1020,"activeCount":87},[],{"intervention":1014,"totalTrials":106,"cells":1022},{"EARLY_PHASE1":1023,"PHASE1":1025,"PHASE2":1027,"PHASE3":1033,"PHASE4":1035,"NA":1037},{"trials":1024,"activeCount":87},[],{"trials":1026,"activeCount":87},[],{"trials":1028,"activeCount":87},[1029],{"nctId":1006,"briefTitle":1007,"status":114,"phases":1030,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1031,"interventions":1032},[78],[23],[997,1014,997],{"trials":1034,"activeCount":87},[],{"trials":1036,"activeCount":87},[],{"trials":1038,"activeCount":87},[],{"intervention":1040,"totalTrials":106,"cells":1041},"ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE",{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1046,"PHASE3":1048,"PHASE4":1050,"NA":1052},{"trials":1043,"activeCount":87},[],{"trials":1045,"activeCount":87},[],{"trials":1047,"activeCount":87},[],{"trials":1049,"activeCount":87},[],{"trials":1051,"activeCount":87},[],{"trials":1053,"activeCount":87},[1054],{"nctId":1055,"briefTitle":1056,"status":423,"phases":1057,"completion":1058,"start":1059,"enrollment":1060,"conditions":1061,"interventions":1062},"NCT00304980","Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status",[81],"2005-04","2003-03",3000,[734],[1040],{"intervention":1064,"totalTrials":106,"cells":1065},"Mass drug administration, praziquantel 10mg\u002Fkg",{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1072,"PHASE4":1074,"NA":1076},{"trials":1067,"activeCount":87},[],{"trials":1069,"activeCount":87},[],{"trials":1071,"activeCount":87},[],{"trials":1073,"activeCount":87},[],{"trials":1075,"activeCount":87},[],{"trials":1077,"activeCount":87},[1078],{"nctId":1079,"briefTitle":1080,"status":114,"phases":1081,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1085,"conditions":1086,"interventions":1088},"NCT02612896","Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa?",[81],"2021-10","2022-02","2016-03",2900,[1087],"Taenia Solium Infection",[1064],{"intervention":1090,"totalTrials":106,"cells":1091},"serological surveillance",{"EARLY_PHASE1":1092,"PHASE1":1094,"PHASE2":1096,"PHASE3":1098,"PHASE4":1100,"NA":1102},{"trials":1093,"activeCount":87},[],{"trials":1095,"activeCount":87},[],{"trials":1097,"activeCount":87},[],{"trials":1099,"activeCount":87},[],{"trials":1101,"activeCount":87},[],{"trials":1103,"activeCount":87},[1104],{"nctId":1105,"briefTitle":1106,"status":114,"phases":1107,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1114},"NCT04701996","Transmission Dynamics of COVID-19 in a Rural Setting of the Democratic Republic of the Congo",[],"2021-12-31","2022-09-30","2020-09-23",1709,[1113],"Covid19",[1090],{"intervention":1116,"totalTrials":106,"cells":1117},"Sodium Stibogluconate with allopurinol",{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1124,"PHASE4":1126,"NA":1128},{"trials":1119,"activeCount":87},[],{"trials":1121,"activeCount":87},[],{"trials":1123,"activeCount":87},[],{"trials":1125,"activeCount":87},[],{"trials":1127,"activeCount":87},[],{"trials":1129,"activeCount":87},[1130],{"nctId":1131,"briefTitle":1132,"status":114,"phases":1133,"primaryCompletion":1134,"completion":1134,"start":1135,"enrollment":1136,"conditions":1137,"interventions":1139},"NCT04699383","Documentation of Patient Outcomes for SSG\u002FAllopurinol Combination Treatment in Ethiopia",[],"2022-12-15","2021-02-15",105,[1138],"Cutaneous Leishmaniasis",[1116],{"intervention":1141,"totalTrials":106,"cells":1142},"mefloquine",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1149,"PHASE4":1151,"NA":1153},{"trials":1144,"activeCount":87},[],{"trials":1146,"activeCount":87},[],{"trials":1148,"activeCount":87},[],{"trials":1150,"activeCount":87},[],{"trials":1152,"activeCount":87},[],{"trials":1154,"activeCount":87},[1155],{"nctId":1156,"briefTitle":1157,"status":114,"phases":1158,"primaryCompletion":1159,"completion":1160,"start":1161,"enrollment":1162,"conditions":1163,"interventions":1164},"NCT00373048","Mefloquine Prophylaxis in HIV-1 Individuals: a Randomized Placebo-controlled Trial",[81],"2007-12","2011-05","2005-10",300,[33],[1141],{"intervention":1166,"totalTrials":106,"cells":1167},"venous blood sample",{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1174,"PHASE4":1176,"NA":1178},{"trials":1169,"activeCount":87},[],{"trials":1171,"activeCount":87},[],{"trials":1173,"activeCount":87},[],{"trials":1175,"activeCount":87},[],{"trials":1177,"activeCount":87},[],{"trials":1179,"activeCount":87},[1180],{"nctId":1181,"briefTitle":1182,"status":114,"phases":1183,"primaryCompletion":1184,"completion":1185,"start":1186,"enrollment":1187,"conditions":1188,"interventions":1189},"NCT05332093","Spatial Analysis of Host-parasite Interactions in Cutaneous Leishmaniasis in Ethiopia",[],"2024-03-30","2024-12-31","2022-03-21",92,[21],[1166,1190],"skin slit",{"intervention":1190,"totalTrials":106,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1194,"activeCount":87},[],{"trials":1196,"activeCount":87},[],{"trials":1198,"activeCount":87},[],{"trials":1200,"activeCount":87},[],{"trials":1202,"activeCount":87},[],{"trials":1204,"activeCount":87},[1205],{"nctId":1181,"briefTitle":1182,"status":114,"phases":1206,"primaryCompletion":1184,"completion":1185,"start":1186,"enrollment":1187,"conditions":1207,"interventions":1208},[],[21],[1166,1190]]